Testing Services

Testing Services-For Research Purposes Only

Biological therapies—monoclonal antibodies, recombinant proteins, fusion proteins, vaccines, and cell- or gene-based products—deliver transformative outcomes yet behave unpredictably in each patient. Therapeutic drug monitoring (TDM) couples trough drug-level measurement with anti-drug antibody (ADA) detection to keep treatment effective, safe, and economical.

Key reasons to test

• Pharmacokinetic variability – weight, albumin, genetics, disease activity, and concomitant drugs can drive levels outside the therapeutic window.
• Immunogenicity – ADA accelerate clearance or neutralize the drug, leading to secondary loss of response.
• Cost-effectiveness – evidence-guided dosing prevents futile escalation or premature switches.
• Guideline support – gastroenterology, rheumatology, dermatology, oncology, and transplant societies now endorse proactive and reactive TDM.

These principles are reflected in clinical practice: measuring trough levels identifies sub- or supra-therapeutic exposure, while ADA assays clarify whether loss of response stems from immunogenicity or insufficient dosing. matriksbiotek.com

Minimum submission – We quote and perform each assay on ≥ 20 serum or plasma samples to ensure statistical power and parallel calibration. 

Who Benefits?

• Clinicians. TDM and ADA data inform dose adjustment, interval extension, or therapy switch, improving outcomes and reducing adverse events. 
• Testing laboratories. SHIKARI® ELISA and T-CAP NAb kits deliver validated, reproducible quantitation, and our team provides custom development and full validation for novel molecules. 
• Patients. Regular monitoring keeps therapy in the therapeutic window, empowering shared decisions and enhancing quality of life. 

Service Portfolio

Why Matriks Biotek?

• Pioneer in biological drug monitoring:  First to commercialize biological-drug monitoring ELISA kits worldwide (SHIKARI®, 2008). 
• Unmatched catalog. Over 120 kits for 43 biologics and 16 SARS-CoV-2 immunoassays—over 106 CE-IVD products. 
• Global adoption. Exported to > 40 countries and trusted by 30 + pharmaceutical companies developing biosimilars. 
• 23 years of expertise. The company founded in 2002. 
• End-to-end quality. ISO 13485:2016 QMS, CE-IVD labeling, NIBSC-referenced panel-sera validation for CoronaHunter® Elisa Kits .

Engagement Workflow

• Sample Logistiics - Dry-ice shipping for distance transfers.
• Quote (≥ 20 samples) – Transparent pricing and timeline.
• Consultation – Ask for information about your project to be implemented.
• Testing & QA – Assays run with calibrators, controls, and strict acceptance criteria.
• Interactive report – Concentrations, ADA titers with confirmation
• Get Started: Email to info@matriksbiotek.com or a video call to discuss your project and receive a customized proposal.

Biological Drug Monitoring: SHIKARI® Kits for Testing 
https://matriksbiotek.com/shikari-products

✔️ All assays are designed for serum or plasma samples and include both drug and anti-drug antibody detection options.

✔️ The testing service is provided solely for research purposes, and the interpretation of the results must be carried out by the specialist who requested the test. Please note that result interpretation is not a service offered by Matriks Biotek.